Uncovering the risks behind recent medication recalls and their impact on Canadians.
Canada Drug Recalls 2025: What Happened?
In 2025, Canada drug recalls have become a public health flashpoint. Health Canada issued multiple recall notices for medications found to contain nitrosamine impurities or incorrect dosages. For instance, a major incident involved JAMP Pharma Corp., which had to pull its JAMP-Pregabalin 50 mg capsules from shelves after discovering they contained 150 mg capsules—posing serious overdose risks.
Additionally, drugs like Amitriptyline, Betahistine, and Sitagliptin were also withdrawn due to contamination by cancer-linked impurities. Altogether, these recalls reflect broader manufacturing and quality control failures that jeopardize patient safety.
Read more: Toxic Drug Crisis in Parksville: A Community-Led Fight for Change
Canada Drug Recalls 2025: What’s Causing This?
So, what exactly is behind the spike in recalls? Health Canada has identified that nitrosamines, classified as probable human carcinogens, are forming during the manufacturing process—especially when certain solvents and reagents interact under specific conditions. These risks were underscored in Health Canada’s 2025 update on nitrosamines.
In particular, the JAMP-Pregabalin recall wasn’t due to the drug compound itself but stemmed from a severe labeling and packaging error. Clearly, such mistakes highlight the gaps in oversight during final-stage production.
Related: Teens Expose Port Alberni Drug Trafficker
Canada Drug Recalls 2025: Who’s Affected and What’s Next?
Understandably, the growing list of Canada drug recalls is affecting thousands of Canadians relying on essential medications. Vulnerable groups—such as seniors and those with chronic conditions—face the highest risks.
As a result, healthcare providers are now actively advising patients to cross-check their prescriptions against Health Canada’s Recalls Database. In tandem, the Canada Vigilance Program allows patients to report adverse effects.
Looking ahead, expect tighter regulations, improved factory audits, and faster communication of recall notices. In the short term, however, medication disruptions could continue as companies work to comply with new impurity detection thresholds. Read more
Takeaway: Medication Safety Is a Shared Responsibility
Ultimately, Canada drug recalls in 2025 are not isolated incidents—they reflect a systemic issue in pharmaceutical quality control. As Canada strengthens its regulatory responses, it’s crucial for patients and healthcare professionals alike to remain vigilant.
Therefore, staying informed, checking your medication regularly, and reporting unusual reactions can help prevent health crises.
